Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

PTC Therapeutics Inc. : PTC THERAPEUTICS PRICES INITIAL PUBLIC OFFERING

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/21/2013 | 11:03am CEST

SOUTH PLAINFIELD, NJ - June 20, 2013 - PTC Therapeutics, Inc. (PTC) today announced the pricing of its initial public offering of 8,372,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares in the offering are being sold by PTC. In addition, the underwriters have an option for a period of 30 days to purchase up to 1,255,800 additional shares of common stock from PTC at the public offering price, less the underwriting discount. PTC's common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the ticker symbol "PTCT" on June 20, 2013.

J.P. Morgan and Credit Suisse are acting as joint book-running managers for the offering. Cowen and Company is acting as co-lead manager and Wedbush PacGrow Life Sciences as co-manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 19, 2013.

The offering is being made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204; or Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, One Madison Avenue, New York, NY 10010; telephone: 800-221-1037; email: newyork.prospectus@credit-suisse.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

ABOUT PTC THERAPEUTICS, INC.

PTC is a biopharmaceutical company focused on the discovery and development of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders and infectious diseases.

CONTACT

Jane Baj

PTC Therapeutics, Inc.

908-912-9167

jbaj@ptcbio.com

Sheryl Seapy

Pure Communications

sheryl@purecommunicationsinc.com


distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
07:01a NESTLE : SC to hear Nestle's plea to destroy 550 tonnes of Maggi
07:01a TESLA MOTORS : says Autopilot not to blame in crash with bus in Germany
07:01a KUNGSLEDEN : divests eight properties and leaves yet another municipality
07:01a DGAP-NEWS : TLG IMMOBILIEN AG erwirbt zwei benachbarte Nahversorgungszentren in Dresden
07:01a DGAP-NEWS : TLG IMMOBILIEN AG acquires two adjoining neighbourhood shopping centres in Dresden
07:01a PR NEWSWIRE : - Start of Day
07:01a ADDEX THERAPEUTICS : Reports First Half 2016 Operating Highlights and Financial Results
07:00a USD/CNH TECHNICAL ANALYSIS : Short Term Range Ahead of China Holiday
06:59a Goldman feels the heat in Asia as IPO engine slows
06:58a MORGAN STANLEY : Naira heads towards N500/USD; Morgan Stanley warns against controls
Latest news
Advertisement
Hot News 
-0.67%Oil Prices Down on Profit-Taking After OPEC Deal
Most Read News
09/29 NXP SEMICONDUCTORS EXPLORES SALE TO QUALCOMM : sources
09/29 Salesforce urges EU to probe Microsoft, Linkedin antitrust issues
09/29DJDEUTSCHE BANK : The Ghost of Lehman Brothers Haunts Deutsche Bank
09/29 Costco quarterly profit beats on lower fees to Visa
09/29 AIRBUS : to merge with its jetmaking unit - sources
Most recommended articles
09/26Predicting the U.S. Elections With The WMA Trump/Clinton Barometer
12:42a THOMAS WILSON : Foxconn's Sharp to spend $570 million on OLED panel production
12:35a NIKKEI 225 TECHNICAL ANALYSIS : 200-Day Moving Average in Play
12:15aDJAsian Shares Rattled by Deutsche Bank
12:15aDJIHS MARKIT : China Manufacturing Gauge Edges Up